At #ESMO24: See analyses of clinically relevant subgroups from postMONARCH, a phase 3 trial investigating a CDK4/6i + ET in HR+, HER2- #AdvancedBreastCancer following progression on a prior CDK4/6i + ET. Learn more here: e.lilly/3Xh1zMQ #BCSM #BreastCancer

At #ESMO24, we look forward to sharing our latest research in #AdvancedBreastCancer and RET-driven cancers. Visit us onsite at the Lilly booth (506) or click here to explore our congress hub: e.lilly/3XHuWsU #CancerResearch #ClinicalTrials #bcsm #lcsm

📌Le 10 FAD "𝐒𝐡𝐚𝐫𝐢𝐧𝐠 𝐞𝐱𝐩𝐞𝐫𝐢𝐞𝐧𝐜𝐞 𝐧𝐞𝐥𝐥’𝐀𝐝𝐯𝐚𝐧𝐜𝐞𝐝 𝐛𝐫𝐞𝐚𝐬𝐭 𝐜𝐚𝐧𝐜𝐞𝐫" sono disponibili on demand fino al 20 𝑑𝑖𝑐𝑒𝑚𝑏𝑟𝑒 2024. Iscriviti qui: ow.ly/v8Np50S16PE #carcinomamammario #cancer #advancedbreastcancer #oncology #formazione

NOW PUBLISHED in Journal of Clinical Oncology: Safety & efficacy results from the EMBER study, a first-in-human trial of an oral SERD, as monotherapy & combined with targeted therapy, in ER+, HER2- #AdvancedBreastCancer. See the publication here: e.lilly/4gfGASX #BCSM #BreastCancer #mBC

🎥We were on the news today introducing the Humanitarian PACT for #advancedbreastcancer to Malawi. This extraordinary program will provide free treatments to patients, bringing hope and care to those who need it most. #HumanitarianPACT The Max Foundation Dan Milner, MD. MSc(Epi), MBA Cathy Scheepers

Tonight on Times Times 360 Malawi our President Fatima Cardoso will address the needs of breast cancer patients in Malawi. #advancedbreastcancer #Malawi #actABC

Full house at The Nairobi Hospital yesterday for the Humanitarian PACT stakeholders meeting. The program will enhance treatment accessibility for HR-positive/HER2-negative #advancedbreastcancer patients in Kenya. Thank you The Nairobi Hospital for the valuable partnership!

I’m stage 4, also known as #SecondaryBreastCancer, #IncurableBreastCancer, #AdvancedBreastCancer and #MetastaticBreastCancer. It’s always good to know the terminology so you can talk to your nursing and oncology teams

Wish me luck! #BreastCancer #SecondaryBreastCancer #AdvancedBreastCancer #Stage4BreastCancer #MetastaticBreastCancer #LivingWithCancer #LivingWithMets #Radiotherapy

We are very excited to be in Liverpool for the Make 2nds Count Patient Summit to meet old friend and form new friendships! #advancedbreastcancer #breastcancer

📌Vi segnaliamo che le 10 FAD "Sharing experience nell'Advanced breast cancer" sono disponibili on-demand fino al 20 dicembre 2024. 👉🏻Iscriviti #gratuitamente qui: ow.ly/ifYI50S170O #carcinomamammario #ecm #cancer #advancedbreastcancer #oncology

See results from the Phase 1a/1b EMBER study, investigating an oral #SERD, in combination with HER2 directed therapy, with or without a CDK 4/6 inhibitor, in ER+, HER2+ #AdvancedBreastCancer. #ASCO24 poster presentation: e.lilly/4dLrzag

See the results from the Phase 3 postMONARCH study, investigating a CDK 4/6 inhibitor + fulvestrant in HR+, HER2- #AdvancedBreastCancer following progression on a prior CDK 4/6i + ET. #ASCO24 Oral Presentation: e.lilly/3UQRXqA #bcsm #CancerResearch #BreastCancer

In conjunction with our partners at ABC Global Alliance we brought together healthcare professionals to provide critical training. 🤝🌍 themaxfoundation.org/breastcancer/ #AdvancedBreastCancer #BreastCancerAwareness #HebronMedicalCenter #GlobalHealthcare

At #ESMOBreast24, see results from ctDNA analyses at baseline in patients with ER+, HER2-, #AdvancedBreastCancer treated with an oral #SERD. Results from the phase I EMBER study: e.lilly/44ztqLo #bcsm #BreastCancer #CancerResearch

The Hebron Medical Center in Cambodia is one of the newest locations to partner with us and ABC Global Alliance in treating advanced breast cancer. #AdvancedBreastCancer #BreastCancerAwareness #HebronMedicalCenter #GlobalHealthcare

NOW PUBLISHED in Annals of Oncology: Final overall survival analysis from the MONARCH 3 study, investigating a CDK 4/6 inhibitor + NSAI in patients with HR+, HER2- #AdvancedBreastCancer. View the results here: e.lilly/3QHChVt #BreastCancer #bcsm #CancerResearch